High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
暂无分享,去创建一个
A. Gadducci | N. Ragni | P. Conte | E. Catsafados | F. Boccardo | A. Rubagotti | R. Rosso | S. Mammoliti | L. Gallo | S. Chiara | R. Algeri | I. Brunetti | M. Bruzzone | G. Foglia | F. Carnino | S. Rugiati | L. Iskra | G. Parodi | A. Bellini | Silvana Chiara | Riccardo Rosso | Francesco Boccardo | P. Conte | Luigi M. Gallo
[1] J. Berek,et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Gore,et al. Impact of doxorubicin on survival in advanced ovarian cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Korn,et al. Dose intensity analysis in advanced ovarian cancer patients. , 1993, British Journal of Cancer.
[4] A. Rubagotti,et al. The impact of received dose intensity on the outcome of advanced ovarian cancer. , 1993, European journal of cancer.
[5] J. Neijt,et al. Advanced epithelial ovarian cancer: 1998 consensus statements. , 1993 .
[6] A. Gadducci,et al. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] N. Geller,et al. Association of disease‐free survival and percent of ideal dose in adjuvant breast chemotherapy , 1990, Cancer.
[8] H. Ngan,et al. A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. , 1989, Chemotherapy.
[9] W. Hryniuk,et al. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Rubagotti,et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] E. McFadden,et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.
[12] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[13] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .